NCT06979596 2026-04-13
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
Clinical Trials
9 trialsNCT06136598 2026-03-19
MK-5684-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02555839 2025-03-28
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
Celgene
Completed
NCT03151811 2024-01-30
OCEAN
Oncopeptides AB
Phase 3 Terminated
NCT02294357 2023-11-01
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Oncotherapeutics
Phase 2 Terminated
NCT03481556 2022-12-19
ANCHOR
Oncopeptides AB
Phase 1/2 Terminated
NCT05052970 2022-02-01
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase 1 Unknown
NCT01636947 2018-09-25
KMEC
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00427999 2016-11-21
INV342
Novartis
Phase 2 Completed